Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
Abbott Laboratories ABT recently launched its Amplatzer Talisman PFO Occlusion System in Europe. The Talisman device aims to treat patent foramen ovale (PFO) patients who have had a stroke and are at ...
Abbott has launched its Amplatzer Tailsman PFO Occlosion System in Europe. The device is designed to treat people with a patent foramen ovale (PFO) who have had a stroke and are at risk of having ...
Please provide your email address to receive an email when new articles are posted on . Supraventricular arrhythmias may be underestimated in patients who have received percutaneous patent foramen ...
St. Luke's Health-Memorial Hospital Lufkin recently announced a significant advancement in cardiovascular care, becoming the first and only hospital in Deep East Texas to successfully perform a ...
While other device-based closures have demonstrated notable rates of atrial fibrillation (5.7–6.6%) and device-related adverse events, the NobleStitch™ system's fully suture-mediated approach ...
The US Food and Drug Administration (FDA) on Friday approved Minnesota-based St. Jude Medical’s Amplatzer PFO Occluder, which is intended to reduce the risk of a stroke for some patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results